Haematologica

Article	Citations
Bence Jones Island in Shepherd Bay, Nunavut: a little known tribute to the legendary physician and chemist’s “thé de voyage”	219
Epigenetic dysregulation of eukaryotic initiation factor 3 subunit E (eIF3E) by lysine methyltransferase REIIBP confers a pro-inflammatory phenotype in t(4;14) myeloma	137
Genome-wide assessment of genetic risk loci for childhood acute lymphoblastic leukemia in Japanese patients	90
Immunochemotherapy plus lenalidomide for high-risk mantle cell lymphoma with measurable residual disease evaluation	87
The first human acute myeloid leukemia genome ever fully sequenced	80
Impact of soluble thrombomodulin and activated protein C on dynamic hemostatic function in trauma: a focus on thrombin generation and clot lysis	70
Intra-marrow delivery of human interleukin-6-loaded biodegradable microspheres promotes growth of patient-derived multiple myeloma cells in mice	70
BCL2 inhibition in adult acute lymphoblastic leukemia: ready for primetime?	70
Genetic risk classification in acute myeloid leukemia patients treated with hematopoietic cell transplantation and post-transplant cyclophosphamide	62
Asparaginase-associated hyperammonemia	61
The polymerase chain reaction, so simple, so clever: the discovery that made minimal residual disease come true	60
Acute myeloid leukemia at first relapse: approaching the precipice	57
Hematopoietic cell transplantation soon after first relapse in acute myeloid leukemia – the CONS	55
Old methods, lasting impact in relapsed/refractory primary mediastinal B-cell lymphoma	54
Recovery of uninvolved heavy/light chain pair immunoparesis in newly diagnosed transplant-eligible myeloma patients complements the prognostic value of minimal residual disease detection	54
PHF6 interacts with the LMO2 complex in T-cell acute lymphoblastic leukemia	53
Asparaginase dosing for acute lymphoblastic leukemia: more questions than answers	53
Comprehensive characterization of human bone marrow microenvironment shows age-related changes	52
Relapsed classic Hodgkin lymphoma; should all patients receive an autologous stem cell transplant? – the PRO	51
Genetic testing guides therapy in children with refractory cytopenias	51
P67 | TALQUETAMAB INDUCES DEEP RESPONSES IN HEAVILY PRE-TREATED PATIENTS WITH SYSTEMIC LIGHT-CHAIN AMYLOIDOSIS	50
P59 | BISPECIFIC ANTIBODIES IN FRAIL AND ELDERLY MULTIPLE MYELOMA PATIENTS WITH ECOG >1: REAL-WORLD IMPACT OF PERFORMANCE STATUS AND DOSE MODIFICATIONS ON OUTCOMES	44
“ASXL1”-erating inflammation and bone marrow fibrosis in myeloproliferative neoplasms	43
Bipartite <i>NUP98</i>::<i>RARA</i>-E412* fusion with a <i>cis</i>-aligned ligand binding domain truncation mutation in atypical acute promyelocytic leukemia	43
Outcomes of patients with relapsed or refractory primary mediastinal B-cell lymphoma after frontline DA-EPOCH-R	42

The patient voice: measuring what matters in lower-risk myelodysplastic syndromes treated with imetelstat	41
The dilemma after chimeric antigen receptor T-cell therapy – to transplant or not?	39
Scott syndrome with novel compound heterozygous pathogenic variants in <i>ANO6</i> and reduced thrombin generation	36
Mutational and copy number analysis at diagnosis and relapse of mantle cell lymphoma	36
CO42 | Dynamic changes after allogeneic stem cell transplantation of extracellular vesicles originated from platelets, endothelial cells and leukocytes after: correlation with acute graft-versus-host	35
CO05 | Identification of <i>wnk1</i> as a druggable target in <i>TAL1</i>-related T-cell acute lymphoblastic leukemia	34
Clonal plasma cell features in light-chain amyloidosis are associated with depth and timing of cardiac response independent of hematologic response	34
Lactoferrin reduces febrile neutropenia in children receiving chemotherapy for hematologic malignancies: a randomized, placebo-controlled trial	33
Venetoclax combined with escalating doses of homoharringtonine, low-dose cytarabine, and granulocyte colony-stimulating factor demonstrates feasibility and tolerability for remission induction in pedi	33
An unusual case of thalassemia intermedia with inheritable complex repeats detected by single-molecule optical mapping	32
Salvage radiotherapy in relapsed/refractory large B-cell lymphoma after failure of CAR T-cell therapy	32
Long-term analysis of the RiBVD phase II trial reveals the unfavorable impact of <i>TP53</i> mutations and hypoalbuminemia in older adults with mantle cell lymphoma; for the LYSA group.	31
Asciminib in chronic myeloid leukemia: a STAMP for expedited delivery?	31
Recognition, prevention, and management of adverse events associated with asparaginase / pegaspargase treatment of acute lymphoblastic leukemia in adults: consensus of an expert panel	30
Infection risk in 158 patients with relapsed/refractory multiple myeloma treated with bispecific antibodies: a single-center experience	30
<i>Erratum</i> to: “Consistent clinical factor VIII equivalency is unlikely for non-factor therapies in hemophilic mice”	30
Venetoclax and azacytidine in childhood primary advanced myelodysplastic syndromes, refractory/relapsed acute myeloid leukemia and therapy-related myeloid neoplasms	30
Next generation sequencing panel for hereditary erythrocytosis in adults with otherwise unexplained erythrocytosis unveils additional genomic variants	29
Next-generation strategies to improve safety and efficacy of adeno-associated virus-based gene therapy for hemophilia: lessons from clinical trials in other gene therapies	29
JAK inhibitor selection in challenging scenarios of myelofibrosis: a review	28
Clonal hematopoiesis by DNMT3A mutations as a common finding in idiopathic splanchnic vein thrombosis	28
Targeting glutaminase is therapeutically effective in ibrutinib-resistant mantle cell lymphoma	28
Anti-CD47 antibody magrolimab with pembrolizumab in patients with relapsed / refractory classic Hodgkin lymphoma	28
Clinical impact of clonal hematopoiesis in hematopoietic cell transplantation: a review, metaanalysis, and call to action	28
CD47 expression in acute myeloid leukemia varies according to genotype	28
Artificial intelligence-based quantitative bone marrow pathology analysis for myeloproliferative neoplasms	28
LILRB4 represents a promising target for immunotherapy by dual targeting tumor cells and myeloid-derived suppressive cells in multiple myeloma	27
Potassium/sodium cation carriers robustly up-regulate CD20 antigen by targeting MYC, and synergize with anti-CD20 immunotherapies to eliminate malignant B cells	27
Teclistamab in relapsed refractory multiple myeloma: a multi-institutional real-world study from the French early access program	27
Soluble SLAMF7 is generated by alternative splicing in multiple myeloma cells	27
Investigating the influence of germline <i>ATM</i> variants in chronic lymphocytic leukemia on cancer vulnerability	27
Running chromosome analysis in leukemia or not, upfront or later?	26
Prognostic relevance of variant allelic frequency for treatment outcomes in patients with acute myeloid leukemia: a study by the Spanish PETHEMA registry	26
Tocilizumab administration in cytokine release syndrome is associated with hypofibrinogenemia after chimeric antigen receptor T-cell therapy for hematologic malignancies	26
First-line MAPK inhibition in pediatric histiocytosis: are we ready?	26
Prehistory of chronic lymphocytic leukemia: clues from the B-cell receptor	26
Autologous-allogeneic versus autologous tandem stem cell transplantation and maintenance therapy with thalidomide for multiple myeloma patients over 60 years of age: a prospective phase II study	26
Lenalidomide maintenance after bortezomib, thalidomide and dexamethasone (VTD) induction and autologous stem cell transplantation: an Italian real-life study of 602 patients	25
New bullets in the fight against cancer	25
TIGIT: an immune checkpoint beyond T cells in chronic lymphocytic leukemia	25
MAPK-kinase mutations and aortic lesions are associated with distribution of circulating monocytes in histiocytosis	25
Cytomegalovirus Triplex vaccine in pediatric hematopoietic stem cell transplant patients at high risk for cytomegalovirus complications: evaluation of vaccine safety, immunogenicity and impact on vire	24
Venetoclax with intensive induction chemotherapy in newly diagnosed adult acute myeloid leukemia: early outcomes from a real-world experience	24
Extracranial internal carotid artery and cerebral infarction in paediatric sickle cell patients	24
Monocyte response to SARS-CoV-2 protein ORF8 is associated with severe COVID-19 infection in patients with chronic lymphocytic leukemia	24
In-depth cytogenetic and immunohistochemical analysis in a real world cohort - reconsidering the role of primary and secondary aberrations in multiple myeloma	23
P23 | DARA-VTD AND ASCT+ LENALIDOMIDE LED TO HIGH COMPLETE REIMISSION AND MINIMAL RESIDUAL DISEASE NEGATIVITY RATES BY NGF: A REAL-WORLD STUDY OF THE TUSCAN MYELOMA NETWORK IN 228 PATIENTS	23
Acute pro-B-cell lymphoblastic leukemia evolving from myelodysplastic neoplasm post cytotoxic therapy: a case report	23
P61 | IMMUNE EFFECTOR CELL COLITIS DURING TREATMENT WITH AN ANTI-BCMA BISPECIFIC ANTIBODY	23
How we changed our approach to venous thromboembolism	22

Safe platelet count for lumbar puncture: are we being overcautious?	22
TNF-α signaling drives myeloid skewing and clonal expansion of stem and progenitor cells in <i>RUNX1</i>-familial platelet disorder	22
Mutations in the <i>RACGAP1</i> gene cause autosomal recessive congenital dyserythropoietic anemia type III	22
SH2 domain-containing inositol 5-phosphatases support the survival of Burkitt lymphoma cells by promoting energy metabolism	22
Anti-CD19 CAR T-cell therapy in relapsed/refractory T-cell/histiocyte-rich large B-cell lymphoma: insights from the French DESCAR-T registry, a LYSA study	22
Advocating prudent D-dimer testing: constructive perspectives and comments on ‘How we manage a high D-dimer’	22
Differentiating pathogenic from bystander autoantibodies in immune thrombocytopenia using intact glycoprotein-deficient megakaryocytes	21
P059 | <i>WT1</i> reduction after induction therapy predicts outcome in AML patients	21
Myeloid lineage switch following CD7-targeted chimeric antigen receptor T-cell therapy in relapsed/refractory T-cell acute lymphoblastic leukemia	21
Blinatumomab is associated with better post-transplant outcome than chemotherapy in children with high-risk first-relapse B-cell acute lymphoblastic leukemia irrespective of the conditioning regimen	21
Predictors of SARS-CoV-2 Omicron breakthrough infection after receipt of AZD7442 (tixagevimab-cilgavimab) for pre-exposure prophylaxis among hematologic malignancy patients	21
Chronic lymphocytic leukemia and associated chronic lung diseases	21
Olverembatinib in accelerated-phase chronic myeloid leukemia: efficacy and safety evaluation	21
<i>CSF3R</i>-mutated chronic neutrophilic leukemia: a two-center study of 44 consecutive patients	21
CO07 | Single-cell sequencing reveals pathways and perturbations predictive of central nervous system dissemination in B-cell acute lymphoblastic leukemia	21
CO58 | Single-cell multi-omics unravels molecular and cellular programs underlying ruxolitinib response in myelofibrosis	20
P023 | SETD2 loss in chronic myeloid leukemia promotes metabolic reprogramming and genomic instability leading to therapeutic resistance and disease progression	20
P005 | ASXL1 variant allele frequency as a modulator of genetic heterogeneity in myelofibrosis	20
Intensive induction therapy with FLAG-idarubicin-venetoclax for fit older high-risk patients with acute myeloid leukemia	20
P009 | Beyond the Dynamic International Prognostic Scoring System: the role of inflammation in myelofibrosis	20
Disrupting adaptive proteostasis to overcome proteasome inhibitor resistance	19
Superior outcomes and high-risk features with carfilzomib, lenalidomide, and dexamethasone combination therapy for patients with relapsed and refractory multiple myeloma: Results of the multicenter KM	19
LP-118 is a novel B-cell lymphoma 2 / extra-large inhibitor that demonstrates efficacy in models of venetoclaxresistant chronic lymphocytic leukemia	19
Molecular measurable residual disease by immunoglobulin gene rearrangements on circulating tumor DNA predicts outcome in diffuse large B-cell lymphoma	19
Glofitamab plus polatuzumab vedotin: a novel safe, and highly effective chemotherapy-free regimen for pediatric relapsed/refractory B-cell non-Hodgkin lymphoma	19
Monitoring relapse in post-transplant acute myeloid leukemia requires integrated assessment, with flow cytometry showing the highest efficacy	19
Emergence of <i>TP53</i> mutation during lenalidomide therapy of myelodysplastic syndrome with del(5q) and its subsequent disappearance following salvage therapy with decitabine	19
Treatment of lower-risk myelodysplastic syndromes	19
National-level dietary patterns and acute myeloid leukemia: a global ecological analysis	19
Impact of central nervous system involvement in adult patients with Philadelphia-negative acute lymphoblastic leukemia: a GRAALL-2005 study	19
Safety and efficacy of zinpentraxin alfa as monotherapy or in combination with ruxolitinib in myelofibrosis: stage I of a phase II trial	19
Major adverse cardiovascular events in immune-mediated thrombotic thrombocytopenic purpura during clinical remission	19
Dexamethasone added to induction and post-remission therapy in older patients with newly diagnosed acute myeloid leukemia: a multicenter, phase II trial (DEXAML-02)	19
Extended exposure to low doses of azacitidine induces differentiation of leukemic stem cells through activation of myeloperoxidase	19
Prognostic impact of Dmax on baseline FDG-PET/CT in newly diagnosed multiple myeloma	18
Myeloid/lymphoid neoplasms associated with eosinophilia and rearrangements of <i>PCM1::JAK2</i> with erythroblastic sarcoma: a case report and literature review	18
Gut microbiome alterations at acute myeloid leukemia diagnosis are associated with muscle weakness and anorexia	18
Epstein-Barr Virus and immune status imprint the immunogenomics of non-Hodgkin lymphomas occurring in immune-suppressed environments	18
Characteristics of clonal cytopenia of undetermined significance in the presence of <i>ZRSR2</i> mutations	18
EZH2 inhibition overcomes immunomodulatory drug resistance in multiple myeloma via a cereblon-dependent pathway	18
Hematologic dysfunction and myeloid neoplasm risk in patients treated with lutetium-177 prostate specific antigen membrane therapy	18
<i>Ex vivo</i> venetoclax sensitivity testing predicts treatment response in acute myeloid leukemia	18
Altered mesenchymal and endothelial subsets in interstitial bone marrow and focal lesions in myeloma patients and SCID-hu mice	17
Landscape of immunoglobulin heavy chain γ gene class switch recombination in patients with adult T-cell leukemia–lymphoma	17
Aspirin is a life-saving drug for patients with acute myocardial infarction	17
Genomics improves risk stratifi cation of adults with T-cell acute lymphoblastic leukemia enrolled in measurable residual disease-oriented trials	17
Identification of a clinicopathologic prognostic index for newly diagnosed large B-cell lymphoma patients treated with R-CHOP	17
COVID-19 thromboembolism is reduced in ambulatory, but not hospitalized patients, following COVID-19 vaccination Short title: COVID-19 thromboembolism	17
von Hippel- Lindau syndrome-related congenital polycythemia and response to belzutifan	17
Anti-HLA class I IgG subclasses skew platelet activation mechanisms in transfusion refractoriness	17
Prior cancer and risk of monoclonal gammopathy of undetermined significance: a population-based study in Iceland and Sweden	17
LSD1/KDM1A and GFI1B repress endothelial fate and induce hematopoietic fate in induced pluripotent stem cell-derived hemogenic endotheliums	17
<i>Ex vivo</i> correction of severe coagulation Factor VII deficiency in patient-derived 3D liver organoids	17
“Bridegroom of blood”- A biblical reference to hemophilia?	17
Reply to the Comment on: “Dexamethasone treatment for COVID-19 is related to increased mortality in hematologic malignancy patients: results from the EPICOVIDEHA Registry”	16
A phase II trial of azacitidine with ipilimumab, nivolumab, or ipilimumab and nivolumab in previously untreated myelodysplastic syndrome	16
αβT- and B-cell-depleted HLA-haploidentical hematopoietic stem cell transplantation in children with myelodysplastic syndromes	16
Comment on "Acute Promyelocytic Leukemia with other <i>RARA</i> rearrangements"	16
More than a Lonca-shot: beating the odds in relapsed/refractory diffuse large B-cell lymphoma	16
An investigation of germline variants of <i>HAVCR2</i> in subcutaneous panniculitis-like T-cell lymphoma and related lesions in a North American population	16
Bedside treatment algorithm for safe administration of 24-hour high-dose methotrexate in adult acute lymphoblastic leukemia	16
Teclistamab therapy for refractory type 1 cryoglobulinemia Teclistamab in type 1 cryoglobulinemia	16
Male sex adversely impacts survival and myeloid malignancy risk in MGUS: a real-world population-based study	16
Single-cell profiling of CD19-directed CAR-T cell phenotypes and immune system dynamics in pediatric B-cell acute lymphoblastic leukemia	16
Long-term outcomes and renal responses following autologous hematopoietic stem cell transplantation for light chain deposition disease: a retrospective study on behalf of the Chronic Malignancies Work	16
Shaping the future of older pa1ents with Philadelphia-nega1ve lymphoblas1c leukemia	16
Phase I study of the safety and pharmacokinetics of CSL889 (hemopexin) in adults with sickle cell anemia	16
P028 | Flow cytometric characterization of myelodysplastic syndrome stem cells: a new prognostic tool	15
P077 | Clinical profiles and treatment approaches in Italian patients with CLL in clinical practice: findings from a European cross-sectional survey	15
P58 | TRIAL IN PROGRESS: QUINTESSENTIAL-2 – A PHASE 3 STUDY OF ARLOCABTAGENE AUTOLEUCEL VS. STANDARD OF CARE IN ADULT PATIENTS WITH RELAPSED AND REFRACTORY MULTIPLE MYELOMA EXPOSED TO LENALIDOMIDE	15
Outcomes of real-world complete responders after fixed-duration glofitamab in relapsed/refractory large B-cell lymphoma	15
P69 | REAL-WORLD USAGE OF HYALURONIDASE-FACILITATED SUBCUTANEOUS IMMUNOGLOBULIN 10% IN PATIENTS WITH MULTIPLE MYELOMA DIAGNOSED WITH SECONDARY IMMUNODEFICIENCY: AN INTERIM ANALYSIS	15
<i>Erratum</i> to: “Lower incidence of chronic graft-<i>versus</i>-host disease after ruxolitinib plus extracorporeal photopheresis <i>versus</i> ruxolitinib alone	15
P079 | Assessment by high resolution ultrasound sonography of patients with chronic lymphocytic leukemia treated with BTK inhibitors. Clinical and pharmacoeconomic impact	15
LDHAL6B is a novel prognostic marker and promotes disease progression in multiple myeloma	15
P70 | NOVEL MONOCLONAL GAMMOPATHY OF UNDETERMINED SIGNIFICANCE CARE PATHWAY FOR THE EARLY DETECTION OF M PROTEIN RELATED DISEASES	15
Genomic analysis of venous thrombosis in children with acute lymphoblastic leukemia from diverse ancestries	15
CO11 | BCOR inactivation in B cells initiates CLL-like disease and enables study of disease evolution in a novel mouse model	15
P040 | Metabolic reprogramming and DNA repair plasticity fuel resistance to long-term CHK1/CHK2 inhibition in B-cell acute lymphoblastic leukemia	15
CAR T-cell treatment of high-risk multiple myeloma: will there be a cure?	15

CNS infiltration by zamtocabtagene autoleucel tandem CD20/CD19 CAR T cells leading to complete remission in a patient with primary CNS lymphoma	15
HBV infection in the era of T-cell engagers in multiple myeloma: unresolved challenges and unmet needs. Comment on: “Hepatitis B virus reactivation following T-cell engager therapy in multiple myeloma	15
Impact of letermovir on Cytomegalovirus-specific T-cells reconstitution after allogeneic hematopoietic stem cell transplantation in the post-transplant cyclophosphamide era	14
Clonal evolution from B-cell acute lymphoblastic leukemia with <i>BCR::ABL1</i> multilineage involvement to acute myeloid leukemia after multiple anti-CD19 chimeric antigen receptor T-cell	14
Pirtobrutinib and venetoclax combination overcomes resistance to targeted and chimeric antigen receptor T-cell therapy in aggressive mantle cell lymphoma	14
The relative importance of platelet integrins in hemostasis, thrombosis and beyond	14
Harnessing the cytotoxic granule exocytosis to augment the efficacy of T-cell-engaging bispecific antibody therapy.	14
TAFRO-like syndrome associated with long-term CAR-T cell persistence after axicabtagene ciloleucel therapy	14
Atypical presentation of <i>RAG1</i>-associated SCID: diagnostic challenges beyond infections and lymphocyte count	14
CD19/CD22-targeted CAR T cells in autoimmune hemolytic anemia after allogeneic hematopoietic stem cell transplantation	14
The International Prognostic Index: still relevant 30 years later	14
Biosimilars in rare diseases: a focus on paroxysmal nocturnal hemoglobinuria	14
Outcomes of children and young adults with B-cell acute lymphoblastic leukemia given blinatumomab as last consolidation treatment before allogeneic hematopoietic stem cell transplantation	14
Type I interferons: leukemia's old foe in the limelight again	14
Introduction. Immunotherapy for childhood malignancies: the future is now	14
LNK/<i>SH2B3</i> as a novel driver in juvenile myelomonocytic leukemia	14
Age-specific mutation profiles and their prognostic implications in pediatric <i>KMT2A</i>-rearranged acute myeloid leukemia	14
The French-American-British classification system for acute myeloid leukemia	14
Duality of Nrf2 in iron-overload cardiomyopathy	14
Entities <i>versus</i> diseases: Myers <i>et al</i>. propose distinct aspects of adult T-cell lymphoma / leukemia.	14
Leon's helmet	14
Rooted in reality, living with hope: post-treatment fertility preservation	14
Cancer-related thrombosis: impact of biological sex on the risk of rethrombosis and bleeding	13
Lipid dysregulation after hematopoietic stem cell transplant	13
PTPN11 mutations define a rare but highly adverse subset of myelodysplastic syndromes	13
The effects of cardio-selective β blockade on diastolic dysfunction in children with sickle cell disease	13
All patients with AML and <i>FLT3</i>-ITD should be transplanted in first remission. Also in the era of tyrosine kinase inhibitors? – the PRO	13
CCRL2 and who? An important driver in <i>TP53-</i>mutant myeloid leukemias	13
Diagnostic challenges and proposed classification of myeloid neoplasms with overlapping features of thrombocytosis, ring sideroblasts and concurrent del(5q) and <i>SF3B1</i> mutations	13
Single-cell analysis of the T-cell receptor repertoire in untreated myeloma patients suggests potential myeloma-reactive CD8+ T-cells are shared between blood and marrow	13
Umbilical cord blood T cells can be isolated and enriched by CD62L selection for use in 'off the shelf' chimeric antigen receptor T-cell therapies to widen transplant options	13
Response to the Comment: “Advocating prudent D-dimer testing: constructive perspectives and comments on “How we manage a high D-dimer”	13
A nationwide Italian GIMEMA survey on tandem autologous stem cell transplantation for newly diagnosed multiple myeloma patients treated with daratumumab, bortezomib, thalidomide and dexamethasone	13
More on the pathogenesis of thrombotic thrombocytopenic purpura. Comment on “Acquired thrombotic thrombocytopenic purpura without detectable anti-ADAMTS13 antibodies: a possible underlying autoimmune	13
Dissecting CD47 expression in lymphoid neoplasms to inform precision immunotherapy with anti-CD47 phagocytic checkpoint blockade	13
Toward chemotherapy-reduced cure for TCF3::HLF B-cell acute lymphoblastic leukemia using CD-19-directed immunotherapy	13
Teclistamab <i>versus</i> B-cell maturation antigen-targeting chimeric antigen receptor T-cell therapy in multiple myeloma: a comparative effectiveness analysis	13
Clinical and sociodemographic predictors of intensive care unit admission following chemotherapy in acute myeloid leukemia	13
Von Willebrand disease: classification and epidemiology	13
Amyloidogenic light chains impair plasma cell survival	12
Elucidation of molecular basis of osteolytic bone lesions in advanced multiple myeloma	12
CO28 | NONO shapes multiple myeloma progression through paraspeckle-dependent and independent pathways	12
CO20 | Immune dysregulation in multiple myeloma: uncovering the role of non-malignant B cells	12
Polytypic B cells, monotypic/monoclonal B-cell proliferations, and neoplastic T cells diverge from <i>TET2</i>-/<i>DNMT3A</i>-mutant clonal hematopoiesis in follicular helper T	12
Racial differences in the proportion of myeloma cases attributable to excess body weight and diabetes mellitus in the United States	12
Therapeutic inhibition of myeloperoxidase with AZD5904 attenuates disease progression in mouse models of early-stage and relapsed multiple myeloma	12
Acute leukemia of ambiguous lineage: the known and the uncertain	12
P016 | A novel insight into the role of CCM genes in myeloproliferative neoplasms	12
CO32 | ARQ531 targets MAPK–S6K1 signaling and synergizes with lenalidomide in RAS-mutant and wild-type multiple myeloma	12
Next generation sequencing-based measurable residual disease detection predicts outcomes in patients with acute myeloid leukemia undergoing allogeneic stem cell transplantation	12
Sex differences in progression of kidney disease in sickle cell disease	12
Clinical perspectives on the optimal use of lenalidomide plus bortezomib and dexamethasone for the treatment of newly diagnosed multiple myeloma	12
Phase I study of the Syk inhibitor sovleplenib in relapsed or refractory mature B-cell tumors	12
ICANS mitigation in high-risk elderly patients treated with CD28 co-stimulatory anti-CD19 CAR-T cells using a standardization protocol: a pilot study	12
Association of <i>NUDT15</i> gene polymorphism with adverse reaction, treatment efficacy, and dose of 6-mercaptopurine in patients with acute lymphoblastic leukemia: a systematic review an	12
P039 | Targeting oncogene-induced senescence in ETV6::RUNX1 pre-leukemic cells	12
Modern, real-world patterns of care and clinical outcomes among patients with newly diagnosed diffuse large B-cell lymphoma with or without double/triple-hit status in the United States	12
The E3 ligase TRIM31 regulates hematopoietic stem cell homeostasis and MLL-AF9 leukemia	12
Myelodysplastic syndrome with cryptic 5q deletions in young male patients showing sustained response to lenalidomide	12
An unusual case of basophilic meningitis revealing a chronicphase chronic myeloid leukemia: a report after almost three years of follow-up	11
Venetoclax and gilteritinib combination for <i>FLT3</i>-mutated relapsed/refractory acute myeloid leukemia: a real-world single-center experience	11
Histiocyte Society blueprint for non-Langerhans cell histiocytosis research: unraveling complex diseases through collaboration	11
Acquired thrombotic thrombocytopenic purpura without detectable anti-ADAMTS13 antibodies: a possible underlying autoimmune mechanism.	11
P77 | LIGHT CHAIN DEPOSITION DISEASE: A RARE CAUSE OF RENAL INJURY WITH EMERGING THERAPEUTIC OPTIONS	11
Efficacy of intravenous high-dose methotrexate in preventing relapse to the central nervous system in R-CHOP(-like)-treated, high-risk, diffuse large B-cell lymphoma patients and its effect on mortali	11
Factor X colocalizes with amyloid light chain deposits in AL amyloidosis: evidence from three patients	11
Functional, biochemical, molecular and clinical characterization of antithrombin c.1157T>C (p.Ile386Thr), a recurrent Polish variant with a founder effect	11
Metabolic profile evolution in relapsed/refractory B-cell non-Hodgkin lymphoma patients treated with CD19 chimeric antigen receptor T-cell therapy and implications in clinical outcome	11
SWI/SNF alterations define a subgroup with poorer outcome among patients with aggressive forms of adult T-cell leukemia/lymphoma	11
An extensive database analysis demonstrates significant increase in platelet quantity in unselected hospitalized patients following treatment with oseltamivir	11
Understanding drug resistance in chronic myeloid leukemia through the lens of leukemic stem cell states: insights from single-cell analyses	11
<i>Erratum</i> to: Prevalence and mortality trends of hemoglobinopathies in Italy: a nationwide study	11
Pharmacologic targeting of the p62 ZZ domain enhances both anti-tumor and bone-anabolic effects of bortezomib in multiple myeloma	11
Follicular lymphoma grade 3B: low grade, high grade or should we skip the grade?	11
Haploidentical transplantation in sickle cell disease: toward donor availability for all patients	11
Adenosine signaling inhibits erythropoiesis and promotes myeloid differentiation	11
The development and preliminary validation of the CTCL-PRO-20: a novel quality of life survey for patients with cutaneous T-cell lymphoma	11
Understanding pharmacological complement inhibition in paroxysmal nocturnal hemoglobinuria	11
Somatic genetic alterations predict hematological progression in GATA2 deficiency	11
The landmark contribution by Erik von Willebrand	11
Hyperplasia, dysplasia and neoplasia are unique pathological entities. Comment on: “Clonal megakaryocyte dysplasia with normal blood values: a covert, thrombosis-prone, early myeloproliferative neopla	11
Defibrotide improves COVID-19-related acute respiratory distress syndrome in myeloma patients after chimeric antigen receptor T-cell treatment without compromising virus-specific and anti-myeloma T-ce	11
Myeloid neoplasms after follicular helper T-cell lymphomas: a real, but limited risk	11
<i>IDH1</i>-mutated B-cell acute lymphoblastic leukemia characterized by oncogenic reprogramming of lipid metabolism	10
Marginal zone lymphoma with anti-factor H IgM and atypical hemolytic uremic syndrome successfully treated with odronextamab	10
Cytomegalovirus reactivation after CD19 CAR T-cell therapy is clinically significant	10
Novel <i>KAT6B::NUTM2B</i> fusion oncogene in congenital acute myeloid leukemia and implications for menin inhibitor therapy	10
Clinical and molecular features of <i>CBL</i>-mutated juvenile myelomonocytic leukemia	10
Treatment-related mutagenic processes in acute lymphoblastic leukemia	10
CO12 | Epigenetic regulation of CD49d expression in chronic lymphocytic leukemia: insights from bimodal CD49d cases	10
P085 | Rewiring tumor-driven inflammation to restore immune surveillance in mantle cell lymphoma	10
Transforming mantle cell lymphoma: the journey across eras	10
Revaccination with pneumococcal conjugate vaccine five years after primary immunization improves immunity in patients with chronic lymphocytic leukemia	10
Circulating tumor DNA at baseline as a prognostic marker in untreated follicular lymphoma	10
Response to Comment on: “Is it time to reduce the doxorubicin dosage in Hodgkin lymphoma therapy?”	10